Emerging therapies for bipolar depression.
D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology / Q000628:therapy*; D018849:Controlled Clinical Trials as Topic; D003987:Dibenzothiazepines / Q000627:therapeutic use; D004351:Drug Resistance; D004599:Electric Stimulation Therapy; D004565:Electroconvulsive Therapy; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D018020:Lithium Compounds / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D012307:Risk Factors; D013405:Suicide; D013685:Telecommunications; D016896:Treatment Outcome; D014630:Vagus Nerve / Q000502:physiology
D000927:Anticonvulsants; D000928:Antidepressive Agents; D003987:Dibenzothiazepines; D018020:Lithium Compounds; D000069348:Quetiapine Fumarate; D008094:Lithium